AbbVie (ABBV) Total Debt (2012 - 2025)

AbbVie has disclosed Total Debt across 14 years of filings, most recently posting $61.4 billion for FY2025.

• In Q1 2026, Total Debt fell 5.51% year-over-year to $64.5 billion; the TTM figure through Mar 2026 stood at $64.5 billion (down 5.51% YoY), while the FY2025 annual figure was $61.4 billion, down 8.5% from the prior year.
• Total Debt fell to $61.4 billion in FY2025, from $67.1 billion in the prior year.
• Over the last five years, Total Debt for ABBV reached as high as $76.7 billion in FY2021 and fell as low as $59.4 billion in FY2023.
• The 5-year median for Total Debt is $63.3 billion (2022), against an average of $65.6 billion.
• Annual changes were most pronounced in 2022 — Total Debt decreased 17.48% — and 2024, when it climbed 13.07%.
• A 5-year view of Total Debt shows it stood at $76.7 billion in 2021, then retreated by 17.48% to $63.3 billion in 2022, then dropped by 6.14% to $59.4 billion in 2023, then gained by 13.07% to $67.1 billion in 2024, then decreased by 8.5% to $61.4 billion in 2025.
• According to Business Quant data, Total Debt over the past three periods registered $61.4 billion, $67.1 billion, and $59.4 billion for FY2025, FY2024, and FY2023 respectively.